BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT), a biopharmaceutical company focused on malignancies related to RAS pathways, has announced new preclinical findings regarding its investigational drug BBO-10203. These results were disclosed at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held recently in South San Francisco, California.
The presented data indicates that BBO-10203 effectively disrupts the interaction between RAS and PI3Kα, leading to the inhibition of RAS-mediated signaling pathways involving AKT in tumor cells. Notably, this drug does so without causing hyperglycemia, a common side effect associated with other treatments.
In addition to its robust monotherapy activity, BBO-10203 demonstrated significant efficacy when used in combination with BBOT”s other inhibitors, such as the KRASG12C ON/OFF inhibitor, BBO-8520, and the pan-KRAS inhibitor, BBO-11818. These combinations showed promising results at well-tolerated dosage levels across various KRAS mutant models.
This new research underscores the potential of BBO-10203 as a viable treatment option for patients with tumors driven by RAS mutations, a challenging area in oncology. The findings highlight not only the drug”s effectiveness but also its safety profile, making it a candidate for future clinical trials.
As the understanding of RAS-driven cancers evolves, the implications of these findings may extend to significant advancements in therapeutic strategies aimed at treating these aggressive malignancies.
